Streetbeat News

Earnings

AS

Amer Sports' shares declined following the announcement of disappointing Q4 adjusted EPS results and the issuance of Q1 and FY24 EPS guidance that fell below analysts' expectations.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:59 pm

AS

Amer Sports projects its FY24 earnings per share (EPS) to be in the range of $0.30-$0.40, which is below the estimated $0.51.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:58 pm

AS

Amer Sports projected its Q1 2024 earnings per share (EPS) to be between $(0.01) and $0.02, significantly below the estimated $0.10.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:58 pm

AS

Amer Sports reported a Q4 2023 adjusted EPS of $(0.110), missing the $0.010 estimate by 1200%, but its sales of $1.315B exceeded the $1.302B estimate by 1%.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:55 pm

MAIA

MAIA Biotechnology is nearing completion of its THIO-101 Phase 2 trial, with updates on survival and response data expected soon. The company is exploring treatments for multiple hard-to-treat cancers, including NSCLC, and has developed over 80 THIO-like compounds for its second-generation telomere targeting program. Its pipeline also includes THIO-102 and THIO-103 clinical trials in planning stages, and IND-enabling studies for second-generation agents.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:47 pm

ESLT

Elbit Systems Ltd. (NASDAQ:ESLT) shares fell after announcing expected non-cash expenses of $52 million for Q4 2023, due to the write-off of inventory and contract assets from closing an underperforming subsidiary and discontinuing a project. The company plans to release its Q4 and full-year 2023 financial results on March 26, 2024. Despite this, Elbit secured a $300 million contract last month for military systems for European armored vehicles. ESLT shares dropped 1.63% in premarket trading.

Portfolio Pulse from Lekha Gupta

March 05, 2024 | 1:45 pm

SOPH

Sophia Genetics shares dropped following a report of disappointing Q4 earnings and a less optimistic outlook for 2024.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 1:44 pm

DNMR

HMY

MLM

NWGL

RPM

As of March 5, 2024, five materials sector stocks are considered overbought based on their RSI values, indicating potential short-term performance concerns. These include Nature Wood Group Limited (NWGL), Harmony Gold Mining Company Limited (HMY), Danimer Scientific, Inc. (DNMR), Martin Marietta Materials, Inc. (MLM), and RPM International Inc (RPM). Each company has recently reported positive developments, yet their high RSI values suggest they may be overvalued.

Portfolio Pulse from Avi Kapoor

March 05, 2024 | 1:37 pm

SFIX

Stitch Fix, Inc. (NASDAQ:SFIX) reported Q2 financial results below expectations and provided a weak revenue forecast for FY24, leading analysts to cut their price targets. The company reported a quarterly loss of 30 cents per share, missing the consensus estimate of a 20-cent loss, and sales of $330.4 million, below the expected $330.85 million. The forecast for Q3 revenue is between $300 million and $310 million, against an estimate of $322.29 million, with FY24 revenue expected to be between $1.29 billion and $1.32 billion, below the consensus of $1.35 billion. Despite this, SFIX shares rose 2.2% to close at $3.28.

Portfolio Pulse from Avi Kapoor

March 05, 2024 | 1:36 pm

APGE

GANX

GTLB

Apogee announced its Phase 1 trial for APG777 exceeded objectives, boosting its stock by 50%. GitLab's Q1 EPS and FY25 forecasts fell short of estimates, leading to a 25% stock drop. Gain Therapeutics will present data on GT-02287 at the AP/PD 2024 conference, causing a 43% stock increase.

Portfolio Pulse from ryanfaloona@benzinga.com

March 05, 2024 | 1:33 pm